Literature DB >> 36059361

The Use of Atypical Antipsychotics in Treating a Pediatric Psychiatric Patient.

Joshua A Jogie1,2, Kinna Parikh3, Sheena Mathew4, Kruthiga Rajasekaran5, Shaista Arain6.   

Abstract

Approaches to enhancing mental health management entail several perspectives and efforts to promote competent treatment. In light of this, we present a case report to describe the nature of events encountered during the management of a psychiatric patient. The paper commences by providing a general introduction and background of the concept of atypical antipsychotics before adding a thesis statement that healthcare providers should be knowledgeable regarding psychopharmacotherapy to effectively design and implement safe patient care. The paper's method involved the review of a case scenario and discussion of the concepts using evidence-based guidance and perspectives. In the case scenario, a pediatric patient significantly gains weight and develops extrapyramidal effects like dystonias, and erratic, jerky neck movements as a consequence of treatment with olanzapine. The most effective care plan involves stopping the medication, reviewing treatment options, and incorporating physical exercise. Most importantly, the plan encourages achieving an adequate heart rate above 100 beats per minute to maintain sufficient perfusion during exercise. The paper concludes by summarizing the perspectives from the studies reviewed.
Copyright © 2022, Jogie et al.

Entities:  

Keywords:  atypical antipsychotics; olanzapine; pediatrics; plan; psychiatry

Year:  2022        PMID: 36059361      PMCID: PMC9434710          DOI: 10.7759/cureus.27594

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  11 in total

Review 1.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 2.  Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Authors:  J T Callaghan; R F Bergstrom; L R Ptak; C M Beasley
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 3.  Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.

Authors:  Madeline M Corrao; Leigh Anne Nelson
Journal:  CNS Drugs       Date:  2022-05-30       Impact factor: 6.497

Review 4.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

Authors:  Stefan Leucht; Andrea Cipriani; Loukia Spineli; Dimitris Mavridis; Deniz Orey; Franziska Richter; Myrto Samara; Corrado Barbui; Rolf R Engel; John R Geddes; Werner Kissling; Marko Paul Stapf; Bettina Lässig; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2013-06-27       Impact factor: 79.321

5.  Real-world effectiveness of antipsychotics.

Authors:  J Tiihonen
Journal:  Acta Psychiatr Scand       Date:  2016-11       Impact factor: 6.392

6.  Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.

Authors:  Taro Kishi; Toshikazu Ikuta; Shinji Matsunaga; Yuki Matsuda; Kazuto Oya; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-11       Impact factor: 2.570

7.  Modeling the communication-satisfaction relationship in hospital patients.

Authors:  Daniel Pelletier; Isabelle Green-Demers; Pierre Collerette; Michael Heberer
Journal:  SAGE Open Med       Date:  2019-04-29

8.  A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future.

Authors:  Leslie Citrome; Joseph P McEvoy; Mark S Todtenkopf; David McDonnell; Peter J Weiden
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-05       Impact factor: 2.570

9.  A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models.

Authors:  Heidi N Boyda; Ric M Procyshyn; Lurdes Tse; Jessica W Y Yuen; William G Honer; Alasdair M Barr
Journal:  PLoS One       Date:  2021-01-28       Impact factor: 3.240

Review 10.  Second-generation antipsychotics and extrapyramidal adverse effects.

Authors:  Nevena Divac; Milica Prostran; Igor Jakovcevski; Natasa Cerovac
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.